Reference drugs for triple combination test drug in Russia [Design Issues]

posted by Beholder  – Russia, 2019-11-13 12:47 (589 d 08:48 ago) – Posting: # 20798
Views: 4,850

Hi to all!

Question mostly for Russian members of the forum but anybody who has smth to add is really welcomed.

There is such a situation: a triple combination (3 molecules in one tablet) will be studied in BE study. As reference drugs we can choose two options:

1. a combination of three separate single drugs (i.e. 3 separate tablets) i.e. 3 tablets
2. a combination of one FDC (2 molecules in one tablet) and a single drug (1 molecule in one tablet), i.e. 2 tablets. All of these drugs are reference drugs according to the GRLS system.

What is your opinion which option to choose?

Thanks in advance for your answers.

Best regards
Beholder

Complete thread:

Activity
 Admin contact
21,540 posts in 4,502 threads, 1,525 registered users;
online 7 (0 registered, 7 guests [including 3 identified bots]).
Forum time: Thursday 22:36 CEST (Europe/Vienna)

Laws are like sausages – it is better
not to see them being made.    Otto von Bismarck

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5